GLIOMA, MALIGNANT

This study tests a new drug called LMP744 in people whose glioblastoma has come back after standard treatment. The drug is designed to kill cancer cells by blocking a key growth signal and interfering with DNA repair. Participants will receive the drug through a vein for 5 days e…

This early-phase trial tests a combination of two drugs—D2C7-IT and 2141-V11—for adults with recurrent malignant glioma, a serious brain cancer. The drugs are delivered directly into the tumor and nearby lymph areas. The main goal is to check safety and find the right dose in 90 …

This early study tests if a piece of belly tissue placed in the brain during surgery can safely bypass the blood-brain barrier in people with recurrent glioblastoma, an aggressive brain cancer. Ten adults will be followed for 6 months to check for side effects like rapid tumor gr…

This phase III trial is testing whether delivering the drug bevacizumab (Avastin) directly to the brain through a catheter, along with standard chemo and radiation, can help people with newly diagnosed glioblastoma live longer. The study will enroll 432 adults with this aggressiv…

This study tests a new surgical technique for people with glioblastoma, an aggressive brain cancer. Surgeons place a piece of the patient's own tissue (from the scalp or skull lining) into the area where the tumor was removed. This tissue flap may help bypass the blood-brain barr…

This study is testing a special type of proton radiation called PRDR for people whose fast-growing brain tumor (high-grade glioma) has come back after prior treatment. The goal is to see if this radiation can help control the tumor and improve survival while keeping side effects …

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This early-phase trial tests an experimental drug called CUE-102 in 18 adults with recurrent glioblastoma, a type of brain cancer that has come back. The drug is a fusion protein designed to help the immune system attack cancer cells. The main goal is to find a safe dose and chec…

This early-phase trial at Children's Hospital of Philadelphia is testing whether a radioactive tracer called 18F-Fluciclovine (Axumin) can improve PET-MRI scans for children and young adults with low-grade glioma. About 30 participants will receive the tracer before starting trea…

This study tests whether a special PET scan called 18F-Fluciclovine can help doctors tell the difference between actual tumor growth and harmless changes caused by treatment in children with high-grade glioma. About 30 children aged 1 to 21 will receive the scan after radiation t…

This study tests a remote cognitive rehabilitation program for adults with slow-growing brain tumors (grade 2 or 3 glioma) who often struggle with memory, attention, and thinking. About 187 participants will either receive the program or standard care. The goal is to see if the p…

This early phase 1 trial is testing an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas who are scheduled for tumor removal surgery. The goal is to see how much of the drug gets into the brain tumor and blood, and whether it affects cholesterol-related pathways. Par…